Afshin Dowlati

32.1k total citations · 6 hit papers
395 papers, 16.2k citations indexed

About

Afshin Dowlati is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Afshin Dowlati has authored 395 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 280 papers in Oncology, 157 papers in Pulmonary and Respiratory Medicine and 149 papers in Molecular Biology. Recurrent topics in Afshin Dowlati's work include Lung Cancer Research Studies (134 papers), Lung Cancer Treatments and Mutations (112 papers) and Cancer therapeutics and mechanisms (64 papers). Afshin Dowlati is often cited by papers focused on Lung Cancer Research Studies (134 papers), Lung Cancer Treatments and Mutations (112 papers) and Cancer therapeutics and mechanisms (64 papers). Afshin Dowlati collaborates with scholars based in United States, Spain and United Kingdom. Afshin Dowlati's co-authors include Joan H. Schiller, Julie R. Brahmer, Robert J. Gray, Michael C. Perry, Rogério Lilenbaum, David H. Johnson, Alan Sandler, Scot C. Remick, Pingfu Fu and Nathan Levitan and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Afshin Dowlati

378 papers receiving 15.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 4.5k citations Robert J. Gray, Joan H. Schiller et al. profile →
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

2019 718 citations Charles M. Rudin, Afshin Dowlati et al. profile →
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data

1999 709 citations Afshin Dowlati, Scot C. Remick et al. profile →
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 503 citations Afshin Dowlati et al. Journal of Clinical Oncology profile →
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

2023 75 citations Afshin Dowlati et al. profile →
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03

2025 18 citations Afshin Dowlati, Anne C. Chiang et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Afshin Dowlati

Since Specialization

Citations

This map shows the geographic impact of Afshin Dowlati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afshin Dowlati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afshin Dowlati more than expected).

Fields of papers citing papers by Afshin Dowlati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Afshin Dowlati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afshin Dowlati. The network helps show where Afshin Dowlati may publish in the future.

Co-authorship network of co-authors of Afshin Dowlati

This figure shows the co-authorship network connecting the top 25 collaborators of Afshin Dowlati. A scholar is included among the top collaborators of Afshin Dowlati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Afshin Dowlati. Afshin Dowlati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 breakdown → 2025 ·Journal of Thoracic Oncology ·Afshin Dowlati, Anne C. Chiang, Andrés Cervantes, Sunil Babu, Erika Hamilton, (unknown), Andrea Tazbirkova, Ivana Sullivan, Cédric van Marcke, Antoîne Italiano, (unknown), Sabeen Mekan, (unknown), Saiama N. Waqar	18
2	A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors 2024 ·Clinical Therapeutics ·Gerald S. Falchook, Amita Patnaik, Debra L. Richardson, R. Donald Harvey, Manish Sharma, Navid Hafez, Erika Hamilton, Sarina A. Piha‐Paul, Minal Barve, Trisha M. Wise‐Draper, Manish R. Patel, Afshin Dowlati, (unknown), Shou‐Ching Tang, (unknown), Izabela A. Malinowska, (unknown), Alina Striha, (unknown)	1
3	1004P Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors 2024 ·Annals of Oncology ·Daniel G. Olson, Afshin Dowlati, Jason J. Luke, Meredith McKean, (unknown), Jae‐Hyun Park, Sho Kitano, (unknown), Yuichiro Kaneko, Gerald Koelsch, (unknown), (unknown), (unknown), (unknown), (unknown)	0
4	Comprehensive analysis of the value of dynamic changes in ctDNA in SCLC. 2024 ·Journal of Clinical Oncology ·Peronne Joseph, Zhengyi Chen, (unknown), Pingfu Fu, Afshin Dowlati	0
5	Subjective and Objective Hearing Loss Among US Adult Cancer Survivors 2023 ·JAMA Otolaryngology–Head & Neck Surgery ·(unknown), Changchuan Jiang, Chi Wen, Hui Xie, Yannan Li, Yaning Zhang, Leila J. Mady, Débora S. Bruno, (unknown), (unknown), Afshin Dowlati, Melinda Laine Hsu	0
6	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer 2023 ·ESMO Open ·Charles M. Rudin, Andrés Cervantes, Afshin Dowlati, Benjamin Besse, Bing Ma, Daniel B. Costa, Peter Schmid, Rebecca S. Heist, Victoria Villaflor, Jessica Spahn, (unknown), Edward Cha, Gregory J. Riely, Scott Gettinger	8
7	698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) 2023 ·Annals of Oncology ·Noura J. Choudhury, Prantesh Jain, Afshin Dowlati, Jonathan R. Thompson, Melissa L. Johnson, Hirva Mamdani, Rachel E. Sanborn, Erin L. Schenk, Rahul Aggarwal, K. Nathan Sankar, Luke Walker, Banmeet S. Anand, Himisha Beltran	5
8	Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer 2022 ·Molecular Cancer Therapeutics ·Gary Wildey, (unknown), Karen McColl, (unknown), Mohammad A. Shatat, Ahmad Perwez, (unknown), Adam Kresak, (unknown), Michael Yang, (unknown), Pingfu Fu, (unknown), Wadad Mneimneh, Ata Abbas, Afshin Dowlati	18
9	Role of immunotherapy in gastro‐enteropancreatic neuroendocrine neoplasms (gep‐nens): Current advances and future directions 2021 ·Journal of Neuroendocrinology ·Fang Liu, (unknown), Afshin Dowlati, (unknown)	6
10	476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results 2021 ·Regular and Young Investigator Award Abstracts ·Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Ulka N. Vaishampayan, (unknown), Jordi Rodón, Bo H. Chao, Bingxia Wang, John F. Gibbs, Vaishali Shinde, Sharon Friedlander, Allison Berger, Christine K. Ward, (unknown), Robert Gharavi, (unknown), Igor Proscurshim, Anthony J. Olszanski	10
11	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study 2019 ·Clinical Cancer Research ·Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone	229
12	The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells 2018 ·Cancer Research ·Sarmishtha De, Daniel J. Lindner, (unknown), Gary Wildey, Afshin Dowlati, George R. Stark	37
13	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors 2016 ·Clinical Cancer Research ·Afshin Dowlati, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John M. Rossi, Michael Bass, Gregory Friberg, Cheryl A. Pickett	16
14	Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer 2014 ·Molecular Cancer Therapeutics ·Josephine Kam Tai Dermawan, Katerina V. Gurova, John J. Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, George R. Stark	55
15	Enhanced Radiosensitization of Lung Adenocarcinoma Cells by Pemetrexed When Combined With Methoxyamine to Inhibit Base Excision Repair 2013 ·International Journal of Radiation OncologyBiologyPhysics ·Tithi Biswas, Ravi B. Patel, Lachelle D. Weeks, (unknown), Afshin Dowlati, Neelesh Sharma, Nancy L. Oleinick, S L Gerson, Mitchell Machtay	0
16	Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer 2008 ·Clinical Cancer Research ·Nancy Lan Guo, Ying-Wooi Wan, Kürşad Tosun, Hong Lin, (unknown), Daniel C. Flynn, Scot C. Remick, Val Vallyathan, Afshin Dowlati, Xianglin Shi, Vincent Castranova, David G. Beer, Yong Qian	81
17	Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 2008 ·Journal of Clinical Oncology ·Rogério Lilenbaum, Rita Axelrod, Sachdev Thomas, Afshin Dowlati, L. Seigel, Donald G. Albert, Karsten Witt, D. Botkin	149
18	Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study 2008 ·Clinical Cancer Research ·Afshin Dowlati, Robert J. Gray, Alan B. Sandler, Joan H. Schiller, David H. Johnson	208
19	Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies 2007 ·Cancer Research ·Zhiwei Yu, Titus J. Boggon, Susumu Kobayashi, (unknown), C. Patrick, Afshin Dowlati, Jeffrey A. Kern, Daniel G. Tenen, Balázs Halmos	57
20	Comparison of positron emission tomography and computed tomography in the mediastinal and extrathoracic staging of non-small cell lung cancer 1996 ·Open Repository and Bibliography (University of Liège) ·Patrick Paulus, Thierry Bury, Roland Hustinx, Afshin Dowlati, P. Rigo	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact